Hypoxia-induced NFATc3 deSUMOylation enhances pancreatic carcinoma progression.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
28 04 2022
Historique:
received: 21 06 2021
accepted: 21 03 2022
revised: 01 03 2022
entrez: 28 4 2022
pubmed: 29 4 2022
medline: 3 5 2022
Statut: epublish

Résumé

The transcriptional regulator nuclear factor of activated T-cells, cytoplasmic 3 (NFATc3) is constitutively activated in several cancer types and plays important roles in cancer development and progression. Heavily phosphorylated NFATc3 resides in the cytoplasm of resting cells, and dephosphorylated NFATc3 translocates to the nucleus to activate expression of target genes in cells exposed to stimuli, for instance, hypoxia. Apart from phosphorylation, various post-translational modifications have been reported to regulate NFAT transcriptional activity. However, the mechanisms remain elusive. Here, we have demonstrated that NFATc3 is activated in human pancreatic ductal adenocarcinoma (PDAC) cells and that excessive activation of NFATc3 is correlated to advanced stages of PDAC and short survival time of PDAC patients. NFATc3 is deSUMOylated at K384 by SENP3 under hypoxia, which impairs the interaction between NFATc3 and phosphokinase GSK-3β, subsequently decreases NFATc3 phosphorylation and increases its nuclear occupancy. Knockdown of SENP3 greatly decreased hypoxia-induced NFATc3 nuclear occupancy. Our results highlight that SENP3-mediated deSUMOylation acts as an essential modulator of NFATc3, which is instrumental in PDAC tumor progression under hypoxia.

Identifiants

pubmed: 35484132
doi: 10.1038/s41419-022-04779-9
pii: 10.1038/s41419-022-04779-9
pmc: PMC9050899
doi:

Substances chimiques

NFATC Transcription Factors 0
NFATC3 protein, human 0
transcription factor NF-AT c3 0
Glycogen Synthase Kinase 3 beta EC 2.7.11.1
Cysteine Endopeptidases EC 3.4.22.-
SENP3 protein, human EC 3.4.22.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

413

Informations de copyright

© 2022. The Author(s).

Références

Biochim Biophys Acta. 2014 Dec;1846(2):297-311
pubmed: 25072963
J Biol Chem. 2006 Jun 9;281(23):15869-77
pubmed: 16608850
J Biol Chem. 2009 Apr 17;284(16):10935-46
pubmed: 19218564
Nat Microbiol. 2020 Mar;5(3):511-524
pubmed: 31988379
Science. 1988 Jul 8;241(4862):202-5
pubmed: 3260404
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cell Death Dis. 2020 Jul 23;11(7):559
pubmed: 32703934
Nat Med. 2016 May;22(5):506-15
pubmed: 27043494
Cancer Res. 2010 Jan 1;70(1):418-27
pubmed: 20028870
Nat Commun. 2018 Aug 8;9(1):3157
pubmed: 30089837
Cancer Lett. 2020 Jan 28;469:301-309
pubmed: 31705931
Cancer Lett. 2020 Jan 28;469:1-10
pubmed: 31610265
EMBO J. 2009 Sep 16;28(18):2748-62
pubmed: 19680224
J Cell Biochem. 2019 Dec;120(12):19254-19273
pubmed: 31489709
J Clin Oncol. 2003 Oct 15;21(20):3798-807
pubmed: 12953099
Blood. 2020 Jan 9;135(2):121-132
pubmed: 31794606
J Cell Sci. 2018 Mar 20;131(6):
pubmed: 29559551
Mol Cell Biol. 2004 May;24(10):4184-95
pubmed: 15121840
Eur J Pharmacol. 2018 Aug 5;832:1-10
pubmed: 29753044
J Biol Chem. 2012 Jul 20;287(30):25510-9
pubmed: 22689573
Front Physiol. 2020 Oct 30;11:558220
pubmed: 33192553
Biochem J. 2010 Sep 1;430(2):335-44
pubmed: 20590526
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188356
pubmed: 32147542
EMBO J. 2010 Nov 17;29(22):3773-86
pubmed: 20924358
Nucleic Acids Res. 2012 Dec;40(22):11380-8
pubmed: 23034805
Science. 1997 Mar 28;275(5308):1930-4
pubmed: 9072970
Cell. 2002 Apr;109 Suppl:S67-79
pubmed: 11983154
Cancer Res. 2010 May 15;70(10):4024-33
pubmed: 20442285
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9959-9968
pubmed: 31019078
Biochim Biophys Acta. 2016 Jan;1863(1):139-47
pubmed: 26522917
Nat Rev Mol Cell Biol. 2012 Dec;13(12):755-66
pubmed: 23175280
Mol Cell. 2021 Jun 3;81(11):2303-2316.e8
pubmed: 33991485
Gastroenterology. 2019 May;156(7):2073-2084
pubmed: 30716326
Trends Biochem Sci. 2007 Jun;32(6):286-95
pubmed: 17499995
Curr Opin Struct Biol. 2007 Dec;17(6):726-35
pubmed: 17919899
Nat Rev Immunol. 2010 Sep;10(9):645-56
pubmed: 20725108
PLoS One. 2014 May 23;9(5):e97999
pubmed: 24859347
J Biol Chem. 2004 Jul 2;279(27):28257-65
pubmed: 15117942

Auteurs

Yingying Tong (Y)

Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.

Zheng Zhang (Z)

Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China.

Yurong Cheng (Y)

Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.

Jing Yang (J)

Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.

Cong Fan (C)

Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.

Xuyang Zhang (X)

Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.

Jiandong Yang (J)

Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.

Li Wang (L)

Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.

Dong Guo (D)

Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, and Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310029, China. dongguo@stu.xmu.edu.cn.
Zhejiang University Cancer Center, Hangzhou, Zhejiang, 310029, China. dongguo@stu.xmu.edu.cn.

Dong Yan (D)

Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China. yd15yt88@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH